<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097808</url>
  </required_header>
  <id_info>
    <org_study_id>BTS1362/19</org_study_id>
    <nct_id>NCT04097808</nct_id>
  </id_info>
  <brief_title>Impact of the Source and Food Matrices on the Bioavailability of Peptan® (Collagen Peptides) in Healthy Subjects</brief_title>
  <official_title>Impact of the Source and Polyphenol-containing Food Matrices on the Bioavailability of Peptan® (Collagen Peptides) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rousselot BVBA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioTeSys GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rousselot BVBA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the comparison of the oral bioavailability of hydroxyproline, a key
      marker for collagen peptide intake, after ingestion of collagen peptides from different
      sources, sizes and together with different food matrices, either containing high or low
      levels of polyphenols.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The absorption (blood) of collagen peptides from bovine, fish and porcine source in different
      sizes and administered together with foods of different polyphenol content will be assessed.
      Pharmacokinetic parameters (AUC0-6h, Cmax and Tmax) after oral single dose administration
      will be determined to estimate the impact of different sources, different peptide sized any
      food matrix.

      The following objectives will be evaluated exploratory by comparison of pharmacokinetic
      parameters from the concentration time curve of hydroxyproline, a key marker of collagen type
      I, between:

        -  different sources of collagen peptides (bovine, fish, porcine)

        -  different sizes of collagen peptides from cattle

        -  food matrices impact on uptake of bovine collagen peptides (dissolved in water vs. food
           matrix 1 vs. food matrix 2).

      Additionally, concentration time curves of further amino acids will be assessed
      descriptively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Actual">October 25, 2019</completion_date>
  <primary_completion_date type="Actual">October 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The clinical study will be performed in a double-blind, randomized, monocentric cross-over design.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC(0-6h)) for hydroxyproline after single dose of the different collagen peptides.</measure>
    <time_frame>pre dose and up to 6 hours post dose</time_frame>
    <description>Pharmakokinetic variable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma concentration after administration (Cmax) for hydroxyproline after single dose of the different collagen peptides</measure>
    <time_frame>pre dose and up to 6 hours post dose</time_frame>
    <description>Pharmakokinetic variable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach the maximum concentration of hydroxyproline (Tmax)</measure>
    <time_frame>pre dose and up to 6 hours post dose</time_frame>
    <description>Pharmakokinetic variable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration-time of essential and not essential amino acids</measure>
    <time_frame>pre dose and up to 6 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>collagen peptide bovine high molecular weight-Water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>source: bovine; standardized to 10 g provided as single dose. Orally applied in water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>collagen peptide bovine low molecular weight-Water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>source: bovine; standardized to 10 g provided as single dose. Orally applied in water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>collagen peptide bovine low molecular weight- food matrix 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>source: bovine; standardized to 10 g provided as single dose. Orally applied in Food matrix 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>collagen peptide bovine low molecular weight- food matrix 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>source: bovine; standardized to 10 g provided as single dose. Orally applied in Food matrix 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>collagen peptide fish low molecular weight-Water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>source: fish; standardized to 10 g provided as single dose. Orally applied in water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>collagen peptide porcine low molecular weight-Water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>source: porcine; standardized to 10 g provided as single dose. Orally applied in water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>collagen peptides</intervention_name>
    <description>Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.</description>
    <arm_group_label>collagen peptide bovine high molecular weight-Water</arm_group_label>
    <arm_group_label>collagen peptide bovine low molecular weight- food matrix 1</arm_group_label>
    <arm_group_label>collagen peptide bovine low molecular weight- food matrix 2</arm_group_label>
    <arm_group_label>collagen peptide bovine low molecular weight-Water</arm_group_label>
    <arm_group_label>collagen peptide fish low molecular weight-Water</arm_group_label>
    <arm_group_label>collagen peptide porcine low molecular weight-Water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Subject is able and willing to sign the Informed Consent Form prior to screening
             evaluations

          -  Sex: female and male (50 % of each gender)

          -  Age: 18-50 years

          -  BMI ≥19 and ≤28 kg/m²

          -  Nonsmoker

        Main Exclusion Criteria:

          -  Relevant history or presence of any severe medical disorder, potentially interfering
             with this study (e.g. mal absorption, chronic gastro-intestinal diseases, heavy
             depression, diabetes, acute cancers within last 3 years except basal cell carcinoma of
             the skin, etc.)

          -  Significant changes in lifestyle or medication (within last 3 mo.) or surgical
             intervention or surgical procedure such as bariatric surgery

          -  Application of corticoids (intravenously, orally or intraarticularly) and other
             immune-suppressing drug (within last 2 weeks)

          -  Blood donation within 1 month prior to study start or during study

          -  Regular intake of drugs or supplements possibly interfering with this study
             (Glucosamine, chondroitin sulfate, hyaluronic acid, omega-3, folic acid,
             curcumin/turmeric, Boswellia serrata, collagen, Vitamin D) within 2 weeks prior to
             study start or during study

          -  Intake of anticoagulants like Heparin, Marcumar etc.

          -  Coffee consumption &gt;3 cups / day

          -  History of hypersensitivity to fish
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Menzel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioTeSys GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioTeSys GmbH</name>
      <address>
        <city>Esslingen</city>
        <zip>73728</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioavailability</keyword>
  <keyword>collagen peptides</keyword>
  <keyword>polyphenols</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

